Bristol Myers Squibb (BMY) Income from Continuing Operations (2009 - 2026)

Bristol Myers Squibb (BMY) reported Income from Continuing Operations of 2679000000.0 for Q1 2026, up 8.81% year-over-year from 2462000000.0 in Q1 2025, and up 146.69% quarter-over-quarter from 1086000000.0 in Q4 2025.

Bristol Myers Squibb (BMY) Income from Continuing Operations (2009 - 2026) Analysis & Trends

Bristol Myers Squibb (BMY) has 18 years of Income from Continuing Operations data on file, last reported at 2679000000.0 in Q1 2026.

  • Income from Continuing Operations for Q1 2026 came in at 2679000000.0, up 8.81% year-over-year; the trailing twelve-month figure through Mar 2026 was 7273000000.0 (up 33.77% YoY), and the FY2025 annual result was 7056000000.0, up 178.99% from the prior year.
  • Income from Continuing Operations rose to 2679000000.0 in Q1 2026 per BMY's latest filing, from 1086000000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 2679000000.0 in Q1 2026 and troughed at 11908000000.0 in Q1 2024.
  • A 5-year average of 893352941.18 and a median of 1684000000.0 in 2024 frame the typical range for Income from Continuing Operations.
  • The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 625.28% in 2024, then soared 1328.95% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 2025000000.0 in 2022, then dropped by 12.99% to 1762000000.0 in 2023, then sank by 95.69% to 76000000.0 in 2024, then soared by 1328.95% to 1086000000.0 in 2025, then soared by 146.69% to 2679000000.0 in 2026.
  • Business Quant data shows BMY's Income from Continuing Operations at 2679000000.0 in Q1 2026, 1086000000.0 in Q4 2025, and 2195000000.0 in Q3 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn 3.30 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn 5.24 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn 697.00 Mn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn -4.21 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn 2.02 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn 2.71 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn 2.68 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 2.68 Bn
Dec 31, 2025 1.09 Bn
Sep 30, 2025 2.20 Bn
Jun 30, 2025 1.31 Bn
Mar 31, 2025 2.46 Bn
Dec 31, 2024 76.00 Mn
Sep 30, 2024 1.22 Bn
Jun 30, 2024 1.68 Bn
Mar 31, 2024 -11.91 Bn
Dec 31, 2023 1.76 Bn
Sep 30, 2023 1.93 Bn
Jun 30, 2023 2.08 Bn
Mar 31, 2023 2.27 Bn
Dec 31, 2022 2.03 Bn
Sep 30, 2022 1.61 Bn
Jun 30, 2022 1.43 Bn
Mar 31, 2022 1.28 Bn
Dec 31, 2021 2.37 Bn
Sep 30, 2021 1.55 Bn
Jun 30, 2021 1.06 Bn